ZNF281 and Ewing sarcoma: The Kaplan–Meier survival probability analysis in Ewing’s sarcoma performed by subdividing patients in high‐ and low‐expressing ZNF281 highlighted a significantly worse prognosis in high expressors (Fig. 4B, log‐rank P = 0.032).